Atlas Trials

Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)

Clinical trial NCT01600716 · COMPLETED

Trial details

NCT number
NCT01600716
Sponsor
Allergan
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Urinary IncontinenceMultiple SclerosisNeurogenic Bladder
Start date
2012-06-13
Primary completion
2014-04-04
Enrollment
144

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.